Targeting neglected kinases for new breast cancer therapies

点击翻译按钮获取中文摘要

Our new company is developing novel medicines for breast and other cancer types. We collaborate with leading university researchers, leveraging their knowledge and expertise to target a previously unaddressed cancer susceptibility. We are creating the first medicines tailored to a specific defect in cancer, building on a validated strategy to modulate protein kinases, a previously successful strategy used to treat a range of cancers.Our grant plan will expand on the original scientific foundation, grow our research team and drug development activities, and build our company skillsets and capabilities through partnerships with other cutting-edge businesses.Successful early drug development is resource-intensive, and our plan is built to secure a valuable patent portfolio and robust business capabilities. Our ongoing research is designed to deliver success through efficient planning and aims to achieve goals that will expand the size and sophistication of our company efforts. We plan to support cancer patients in need, through identification and delivery of novel therapies. Success will increase our product value, making it attractive for further investment and collaboration with global pharmaceutical companies.